Form 8-K - Current report:
SEC Accession No. 0001650664-24-000144
Filing Date
2024-12-17
Accepted
2024-12-17 16:17:32
Documents
13
Period of Report
2024-12-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K edit-20241216.htm   iXBRL 8-K 24905
  Complete submission text file 0001650664-24-000144.txt   148853

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT edit-20241216.xsd EX-101.SCH 1875
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT edit-20241216_lab.xml EX-101.LAB 21885
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT edit-20241216_pre.xml EX-101.PRE 12591
15 EXTRACTED XBRL INSTANCE DOCUMENT edit-20241216_htm.xml XML 2714
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37687 | Film No.: 241555879
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)